Immuneering Co. (NASDAQ:IMRX – Get Rating) has been assigned an average rating of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $29.13.
A number of research firms have recently weighed in on IMRX. Zacks Investment Research raised shares of Immuneering from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Wednesday. Oppenheimer began coverage on shares of Immuneering in a research note on Thursday, March 31st. They issued an “outperform” rating and a $25.00 price target on the stock.
In other news, Director Ann E. Berman purchased 6,000 shares of the firm’s stock in a transaction on Tuesday, March 15th. The stock was bought at an average cost of $6.40 per share, for a total transaction of $38,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired 9,900 shares of company stock valued at $69,201 over the last 90 days.
Shares of NASDAQ:IMRX opened at $4.42 on Thursday. Immuneering has a 12-month low of $4.11 and a 12-month high of $33.99. The company’s fifty day moving average is $6.44 and its two-hundred day moving average is $13.79.
Immuneering (NASDAQ:IMRX – Get Rating) last posted its quarterly earnings results on Thursday, March 10th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03). The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.60 million. On average, sell-side analysts forecast that Immuneering will post -2.01 earnings per share for the current fiscal year.
Immuneering Company Profile (Get Rating)
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.
- Get a free copy of the StockNews.com research report on Immuneering (IMRX)
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.